- Home
- USEA vs TXMD Comparison
USEA vs TXMD Comparison
Compare USEA & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | TXMD |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 24.3M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | USEA | TXMD |
|---|---|---|
| Price | $3.08 | $2.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 101.9K | 29.8K |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | ★ N/A | $108.75 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $1.42 | $0.99 |
| 52 Week High | $3.16 | $2.95 |
Technical Indicators
Market Signals| Indicator | USEA | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 74.50 | 54.44 |
| Support Level | $2.48 | $2.15 |
| Resistance Level | N/A | $2.31 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 98.00 | 43.75 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.